Status:
COMPLETED
Vildagliptin and the Glucagon Response to Hypoglycemia in Type 1 Diabetes
Lead Sponsor:
Lund University
Conditions:
Diabetes
Hypoglycemia
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The study examines whether DPP-4 inhibition by vildagliptin affects the glucagon counterregulatory response to hypoglycemia in type 1 diabetes.
Detailed Description
Vildagliptin (50 mg BID) or placebo is given as add-on to insulin treatment for four weeks in patients with type 1 diabetes. Then, a hypoglycemic clamp (2.5 mmol/l glucose) is undertaken with the dete...
Eligibility Criteria
Inclusion
- Type 1 diabetes
- Age \>18 years
- HbA1c 6.5-8,5%
Exclusion
- Pregnancy
- Lactation
- Acute infection
- Liver disease
- Treatment with cortisol
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT01147276
Start Date
September 1 2010
End Date
December 1 2011
Last Update
September 25 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Clinical Sciences Lund, Lund University
Lund, Sweden, 221 84